Praxim Granted Patents Related to Computer and Robotic-Assisted Knee Replacement Products

Share Article

OMNIlife science, Inc. (a subsidiary of Orthopaedic Synergy, Inc.) today announced the United States Patent and Trademark Office granted Praxim, OMNIlife science’s sister company, two additional patents relating to their innovative computer and robotic-assisted surgery platform.

OMNIlife science, Inc. (a subsidiary of Orthopaedic Synergy, Inc.) today announced the United States Patent and Trademark Office granted Praxim, OMNIlife science’s sister company, two additional patents relating to their innovative computer and robotic-assisted surgery platform. The first patent, entitled ‘System for determining the position of a knee prosthesis’, issued under U.S. Patent No. 8,126,533 relates to Praxim’s proprietary BoneMorphing® technology for knee replacement surgery. The second patent, entitled ‘Guiding device for bone cutting’, was issued under U.S. Patent No. 8,096,997, relates to the Apex Robotic Technology (A.R.T.) platform.

BoneMorphing is a process that enables surgeons to intra-operatively create a three dimensional model of the patient’s knee joint, without the added costs and unnecessary exposure to radiation incurred during pre-operative imaging modalities such as CT or MRI. In knee replacement surgery, precise implant positioning, sizing and soft-tissue balancing are essential factors for achieving a good outcome. Praxim’s 3D modeling technology allows surgeons to better visualize and optimize the fit of the implant to the individual anatomy of each patient.    A key aspect of knee replacement surgery is a surgical plan that addresses both the patient’s soft-tissues and ligament balancing; BoneMorphing allows this to occur intra-operatively.

Additional patient and economic benefits are attained when BoneMorphing is coupled with Apex Robotic Technology (“ART”), a robotic cutting guide that precisely aligns the guide to the surgical plan. ART supports the surgeon’s ability to make more precise and efficient bone cuts than previously allowed with conventional navigated blocks, reducing intra-operative time and complexity. Since fewer instruments are required to perform the procedure, hospitals can better optimize logistics and lower instrument processing costs.

“We believe these newly granted patents strengthen our company’s IP portfolio, and underline our commitment to developing innovative technologies that improve patient care.” said George Cipolletti, Chief Executive Officer of OMNIlife science, Inc. and Orthopaedic Synergy, Inc. “The system, as well as comprehensive training and user support, is provided at no cost to the hospital or surgeons. Therefore, the driving value of this product lies in its ability to offer enhanced accuracy for the surgeon and patient, without adding more operative time than a conventional total knee procedure.”

About OMNIlife science, Inc.
OMNIlife science, Inc. was founded in 1999 as an organization committed to the design, manufacture and distribution of high quality orthopaedic devices. Our corporate headquarters are located in East Taunton, Massachusetts. Our products are prescribed by orthopaedic surgeons for their patients who require total joint replacement. OMNI is ISO 13485 certified and its products are FDA cleared and CE approved. OMNI is emerging as a leader in modular hip stem technology and total knee replacement systems. We continue to challenge the design and functionality of our products based on continued advances in reconstructive surgical techniques, anatomic and biomechanical data, as well as input from surgeons. Our corporate strategic objectives include continued growth through line extensions to our hip and knee product offerings as well as the introduction of new products that will complement our current product portfolio and allow us to provide new clinical options for our customers. Additional information can be found at http://www.omnils.com.

About PRAXIM, Inc.
Praxim™, Inc. develops and commercializes advanced automated systems, software and instruments in order to make total knee arthroplasty less-invasive, more reliable, faster and more cost-effective for both patients and surgeons. The Company’s technology platform addresses key issues associated with conventional surgical procedures – including the malalignment of bones that ultimately lead to joint failure. These can be avoided by providing highly innovative imaging protocols and advanced smart instrumentation in the operating room. Additional information can be found at http://www.praxim.fr.

About Orthopaedic Synergy, Inc.
Orthopaedic Synergy, Inc. functions as a holding company for OMNIlife science, Inc., Enztec Limited and PRAXIM, SA. Together these companies represent a global reconstructive orthopaedic concern that is committed to the design, manufacture and distribution of high quality orthopaedic devices. Company objectives include continued growth through strategic acquisition of organizations with complementary technology. The goal is to acquire firms that enhance the development of line extensions to our company’s current product offerings as well as innovative new products that provide improved clinical options for our customers. Additional information can be found at http://www.orthopedicsynergy.com.

Share article on social media or email:

View article via:

Pdf Print

Contact Author

Lisa Cabral
Visit website